Personalized medicine in mesothelioma

1 Views

07/02/23

Dean Fennell, FRCP, PHD, University Hospitals of Leicester NHS Trust, Leicester, UK, discusses precision medicine in mesothelioma, highlighting the main challenges associated with the implementation of personalized medicine, including the prevalence of tumor suppressor genes which are not typically associated as druggable targets, as well as the potential of umbrella trials in mesothelioma. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.